Mineralys CMO exercises options, sells 2,170 shares

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. Chief Medical Officer David Malcom Rodman exercised stock options for 2,170 shares of common stock at $16.00 per share and then sold 2,170 shares in an open-market transaction at $27.38 per share.

These transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on October 6, 2025. Following the sale, he directly holds 76,140 shares of Mineralys Therapeutics common stock.

Insider Trade Summary 10b5-1

Exercise and Sale: 2,170 shares ($25K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Rodman David Malcom

Role Chief Medical Officer

Sold 2,170 shs ($59K)

Approx. gross sale proceeds $59K

Approx. exercise cost $35K

Approx. pre-tax spread $25K

Type	Security	Shares	Price	Value
Exercise	Stock Option	2,170	$0.00	$0.00
Exercise	Common Stock	2,170	$16.00	$35K
Sale	Common Stock	2,170	$27.38	$59K

Holdings After Transaction: Stock Option — 21,706 contracts (Direct); Common Stock — 76,140 shares (Direct)

Footnotes (2)

1. F1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.
2. F2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Key Figures

Options exercised: 2,170 shares Exercise price: $16.00 per share Shares sold: 2,170 shares +4 more

7 metrics

Options exercised 2,170 shares Stock option exercise into common stock

Exercise price $16.00 per share Stock option exercise price

Shares sold 2,170 shares Open-market sale of common stock

Sale price $27.38 per share Price for open-market sale

Post-sale holdings 76,140 shares Common stock held directly after transactions

Option expiration February 9, 2033 Expiration date of exercised stock option

10b5-1 adoption date October 6, 2025 Adoption date of Rule 10b5-1 trading plan

Key Terms

Stock Option, Rule 10b5-1 trading plan, open-market sale, exercise price, +1 more

5 terms

Stock Option financial

"The insider held a Stock Option that was exercised for 2,170 shares."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

Rule 10b5-1 trading plan regulatory

"These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

open-market sale financial

"The filing describes the transaction as an open-market sale of 2,170 common shares."

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

exercise price financial

"The stock option carried a $16.00 exercise price per share."

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

derivative security financial

"The Form 4 notes an Exercise or conversion of derivative security for the stock option."

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Mineralys Therapeutics (MLYS) report for David Malcom Rodman?

Mineralys Therapeutics reported that Chief Medical Officer David Malcom Rodman exercised options for 2,170 shares at $16.00 and sold 2,170 common shares at $27.38. These moves combined an option exercise with an immediate open-market sale on the same date.

How many Mineralys Therapeutics (MLYS) shares does the CMO hold after this Form 4?

After the reported transactions, Chief Medical Officer David Malcom Rodman directly holds 76,140 shares of Mineralys Therapeutics common stock. This figure reflects his position after exercising 2,170 options and selling 2,170 shares in an open-market transaction on the same date.

At what prices did the Mineralys Therapeutics (MLYS) insider exercise and sell shares?

The insider exercised stock options at an exercise price of $16.00 per share and sold 2,170 common shares at $27.38 per share. This reflects a typical exercise-and-sell pattern where options are converted into shares and then sold in the open market.

Was the Mineralys Therapeutics (MLYS) insider trade under a Rule 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on October 6, 2025. Such plans pre-schedule trades, indicating the timing of this exercise-and-sale sequence was predetermined rather than a spontaneous market-timing decision.

What type of derivative security did the Mineralys Therapeutics (MLYS) insider exercise?

The insider exercised a stock option covering 2,170 underlying shares of Mineralys Therapeutics common stock with a $16.00 exercise price and a February 9, 2033 expiration date. Exercising converted the option into common shares, which were then sold in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/13/2026 - 09:13 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rodman David Malcom

(Last) (First) (Middle)

150 N. RADNOR CHESTER RD.

SUITE F200

(Street)

RADNOR PENNSYLVANIA 19087

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Mineralys Therapeutics, Inc. [ MLYS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/09/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/09/2026		M(1)		2,170	A	$16	78,310	D
Common Stock	04/09/2026		S(1)		2,170	D	$27.38	76,140	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$16	04/09/2026		M(1)			2,170	(2)	02/09/2033	Common Stock	2,170	$0	21,706	D

Explanation of Responses:

1. These transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on October 6, 2025.

2. The stock option vested as to 25% of the underlying shares on the first anniversary of the grant date, with the remaining shares vesting in 36 substantially equal monthly installments thereafter.

Remarks:

	/s/ Adam Levy, Attorney-in-fact	04/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)